Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 7-Day Trial for You or Your Team.

Learn More →

OMEGA, a Randomized, Placebo-Controlled Trial to Test the Effect of Highly Purified Omega-3 Fatty Acids on Top of Modern Guideline-Adjusted Therapy After Myocardial Infarction

OMEGA, a Randomized, Placebo-Controlled Trial to Test the Effect of Highly Purified Omega-3 Fatty... Epidemiology and Prevention OMEGA, a Randomized, Placebo-Controlled Trial to Test the Effect of Highly Purified Omega-3 Fatty Acids on Top of Modern Guideline-Adjusted Therapy After Myocardial Infarction Bernhard Rauch, MD; Rudolf Schiele, MD; Steffen Schneider, PhD; Frank Diller; Norbert Victor, PhD; Helmut Gohlke, MD; Martin Gottwik, MD; Gerhard Steinbeck, MD; Ulrike Del Castillo; Rudolf Sack, MD; Heinrich Worth, MD; Hugo Katus, MD; Wilhelm Spitzer, MD; Georg Sabin, MD; Jochen Senges, MD; for the OMEGA Study Group Background—There is no randomized, double-blind trial testing the prognostic effect of highly purified omega-3 fatty acids in addition to current guideline-adjusted treatment of acute myocardial infarction. Methods and Results—OMEGA is a randomized, placebo-controlled, double-blind, multicenter trial testing the effects of omega-3-acid ethyl esters-90 (1 g/d for 1 year) on the rate of sudden cardiac death in survivors of acute myocardial infarction, if given in addition to current guideline-adjusted treatment. Secondary end points were total mortality and nonfatal clinical events. Patients (n3851; female, 25.6%; mean age, 64.0 years) were randomized in 104 German centers 3 to 14 days after acute myocardial infarction from October 2003 until June 2007. Acute coronary angiography was performed in 93.8% and acute percutaneous coronary intervention in 77.8% of all http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Circulation Wolters Kluwer Health

OMEGA, a Randomized, Placebo-Controlled Trial to Test the Effect of Highly Purified Omega-3 Fatty Acids on Top of Modern Guideline-Adjusted Therapy After Myocardial Infarction

Senges, Jochen
Circulation , Volume 122 (21) – Nov 1, 2010
Download PDF
8 pages

Loading next page...
 
/lp/wolters-kluwer-health/omega-a-randomized-placebo-controlled-trial-to-test-the-effect-of-3jc3C4eAT9

References

References for this paper are not available at this time. We will be adding them shortly, thank you for your patience.

ISSN
0009-7322
eISSN
1524-4539
DOI
10.1161/CIRCULATIONAHA.110.948562
pmid
21060071
Publisher site
See Article on Publisher Site

Abstract

Epidemiology and Prevention OMEGA, a Randomized, Placebo-Controlled Trial to Test the Effect of Highly Purified Omega-3 Fatty Acids on Top of Modern Guideline-Adjusted Therapy After Myocardial Infarction Bernhard Rauch, MD; Rudolf Schiele, MD; Steffen Schneider, PhD; Frank Diller; Norbert Victor, PhD; Helmut Gohlke, MD; Martin Gottwik, MD; Gerhard Steinbeck, MD; Ulrike Del Castillo; Rudolf Sack, MD; Heinrich Worth, MD; Hugo Katus, MD; Wilhelm Spitzer, MD; Georg Sabin, MD; Jochen Senges, MD; for the OMEGA Study Group Background—There is no randomized, double-blind trial testing the prognostic effect of highly purified omega-3 fatty acids in addition to current guideline-adjusted treatment of acute myocardial infarction. Methods and Results—OMEGA is a randomized, placebo-controlled, double-blind, multicenter trial testing the effects of omega-3-acid ethyl esters-90 (1 g/d for 1 year) on the rate of sudden cardiac death in survivors of acute myocardial infarction, if given in addition to current guideline-adjusted treatment. Secondary end points were total mortality and nonfatal clinical events. Patients (n3851; female, 25.6%; mean age, 64.0 years) were randomized in 104 German centers 3 to 14 days after acute myocardial infarction from October 2003 until June 2007. Acute coronary angiography was performed in 93.8% and acute percutaneous coronary intervention in 77.8% of all

Journal

Circulation – Wolters Kluwer Health

Published: Nov 1, 2010

There are no references for this article.